Dr. Antonio Gasbarrini
Claim this profileFondazione Policlinico Universitario Agostino Gemelli IRCCS
Clinical Trials Antonio Gasbarrini is currently running
Obefazimod
for Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
Recruiting
0 awards
Phase 2
4 criteria
Vedolizumab
for Crohn's Disease
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical symptoms + biomarkers is superior to a target of clinical symptoms + biomarkers alone in achieving CS-free endoscopic remission measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD). Qualified participants will be randomly assigned in a 1:1 ratio to one of 2 different target treatment groups. Group 1: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH. Group 2: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.
Recruiting
3 awards
Phase 4
3 criteria
More about Antonio Gasbarrini
Clinical Trial Related
1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Antonio Gasbarrini has experience with
- Mirikizumab
- ABX464
- Obefazimod
- TAK-279
- Vedolizumab
Breakdown of trials Antonio Gasbarrini has run
Crohn's Disease
Ulcerative Colitis
Colitis
Crohn's disease
Inflammatory Bowel Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Antonio Gasbarrini specialize in?
Antonio Gasbarrini focuses on Crohn's Disease and Ulcerative Colitis. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Antonio Gasbarrini currently recruiting for clinical trials?
Yes, Antonio Gasbarrini is currently recruiting for 3 clinical trials in Roma Lazio. If you're interested in participating, you should apply.
Are there any treatments that Antonio Gasbarrini has studied deeply?
Yes, Antonio Gasbarrini has studied treatments such as Mirikizumab, ABX464, Obefazimod.
What is the best way to schedule an appointment with Antonio Gasbarrini?
Apply for one of the trials that Antonio Gasbarrini is conducting.
What is the office address of Antonio Gasbarrini?
The office of Antonio Gasbarrini is located at: Policlinico Gemelli - Università Cattolica del Sacro Cuore, Roma, Lazio 00168 Italy. This is the address for their practice at the Policlinico Gemelli - Università Cattolica del Sacro Cuore.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.